# EDGAR Filing Document

**Accession Number:** 0001598599
**File Stem:** 0001157523-23-000443
**Filing Date:** 2023-3
**Character Count:** 7713
**Document Hash:** 5ab85b28cb3b46f84afe5245d4457f98
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001157523-23-000443.hdr.sgml**: 20230316

**ACCESSION NUMBER**: 0001157523-23-000443

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20230316

**FILED AS OF DATE**: 20230316

**DATE AS OF CHANGE**: 20230316

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Innate Pharma SA
- **CENTRAL INDEX KEY:** 0001598599
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** I0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39084
- **FILM NUMBER:** 23737010

**BUSINESS ADDRESS:**
- **STREET 1:** 117 AVENUE DE LUMINY
- **STREET 2:** BP 30191
- **CITY:** MARSEILLE
- **STATE:** I0
- **ZIP:** 13009
- **BUSINESS PHONE:** 33430303030

**MAIL ADDRESS:**
- **STREET 1:** 117 AVENUE DE LUMINY
- **STREET 2:** BP 30191
- **CITY:** MARSEILLE
- **STATE:** I0
- **ZIP:** 13009

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Innate Pharma, SA
- **DATE OF NAME CHANGE:** 20140129

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

#### <br>

### FORM 6-K

#### REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES

#### EXCHANGE ACT OF 1934

#### Date of report: For the month of March 2023

#### Commission File Number: 001-39084

### Innate Pharma S.A.
(Translation of registrant's name into English)

#### 117 Avenue de Luminy—BP 30191

#### 13009 Marseille, France

#### + 33 (0) 4 30 30 30
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [ X ]&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Form 40-F [ ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): [ ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): [ ]

------

#### EXHIBIT INDEX

---

| | |
|:---|:---|
| **<u>Exhibit</u>** | **<u>Description</u>** |
| [<u>99.1</u>](a53362465ex99_1.htm) | [\[Press Release dated March 16, 2023\]](a53362465ex99_1.htm) |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br>

------

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **INNATE PHARMA S.A.** | **INNATE PHARMA S.A.** |
| Date: March 16, 2023&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;  | By: | /s/ Mondher MAHJOUBI |
|  | Name: | Mondher Mahjoubi |
|  | Title: | Chairman of the Executive Board and Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**<br>

# **Innate Pharma Announces Conference Call and Webcast for Full Year 2022 Financial Results** 
MARSEILLE, France--(BUSINESS WIRE)--March 16, 2023--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("**Innate**" or the "**Company**"), today announced that the Company will hold a conference call on Thursday, March 23, 2023 at 2 p.m. CET / 9 a.m. EDT, following the release of its financial results for the full year ending December 31, 2022.

Speakers during the call will be:

* Mondher Mahjoubi, Chief Executive Officer 

* Joyson Karakunnel, Executive Vice President, Chief Medical Officer 

* Yannis Morel, Executive Vice President, Product Portfolio Strategy & Business Development 

* Frédéric Lombard, Senior Vice President, Chief Financial Officer 

 **<u>Details for the Virtual Event</u>**

 **The live webcast will be available at the following link:** <br> https://events.q4inc.com/attendee/611394672

Participants may also join via telephone using the following registration link: https://registrations.events/direct/Q4E60253

This information can also be found on the Investors section of the Innate Pharma website, www.innate-pharma.com. A replay of the webcast will be available on the Company website for 90 days following the event.

 **About Innate Pharma:**

Innate Pharma S.A. is a global, clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.

Innate Pharma's broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.

Innate is a pioneer in the understanding of natural killer cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca.

Headquartered in Marseille, France, with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at www.innate-pharma.com.

------

 **Information about Innate Pharma shares:**

---

| | |
|:---|:---|
| **ISIN code** <br> **Ticker code** <br> **LEI**  | FR0010331421 <br> Euronext: IPH Nasdaq: IPHA <br> 9695002Y8420ZB8HJE29  |

---

 **Disclaimer on forward-looking information and risk factors:**

This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including "believe," "potential," "expect" and "will" and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company's commercialization efforts and the Company's continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority ("AMF"), which is available on the AMF website http://www.amf-france.org or on Innate Pharma's website, and public filings and reports filed with the U.S. Securities and Exchange Commission ("SEC"), including the Company's Annual Report on Form 20-F for the year ended December 31, 2021, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

## Contacts
 **<u>Investors and Media</u>** <br>**Innate Pharma** <br> Henry Wheeler <br> Tel.: +33 (0)4 84 90 32 88 <br> Henry.wheeler@innate-pharma.fr

 **NewCap** <br> Arthur Rouillé <br> Tel.: +33 (0)1 44 71 00 15 <br> innate@newcap.eu